BioNTech SE - American Depositary Shares (BNTX)

Investors buying this biotech stock now will get its pipeline essentially for free.

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Both have attracted considerable attention from Wall Street recently.

The company is coming back into the spotlight thanks to recent developments.

BioNTech is preparing for its next phase.

COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data.

BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

They may not remain cheap for too much longer.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Investors can find much better opportunities.

This may be an excellent deal for those focused on the long game.

Recent performances don't tell the whole story.

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the Cambridge-based biotechnology pioneer is mid-pivot into what CEO Stéphane Bancel describes as "Moderna 2.0." The company that once boasted a market capitalization exceeding $150 billion during the [...]

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper echelons of the S&P 500 performance charts. This rally marks a definitive end to the "post-pandemic

Nothing about the recent past, present, or foreseeable future seems all that compelling.

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion